home / stock / acogf / acogf news


ACOGF News and Press, Alpha Cognition Inc From 03/05/24

Stock Information

Company Name: Alpha Cognition Inc
Stock Symbol: ACOGF
Market: OTC
Website: alphacognition.com

Menu

ACOGF ACOGF Quote ACOGF Short ACOGF News ACOGF Articles ACOGF Message Board
Get ACOGF Alerts

News, Short Squeeze, Breakout and More Instantly...

ACOGF - Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7 th . This event is sponsored by Zacks Small-Cap Research. Individual investors, inst...

ACOGF - Alpha Cognition to Present at the Life Science Investor Forum March 7th

VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (CSE: ACOG)(OTCQB: ACOGF) , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today an...

ACOGF - Alpha Cognition Provides Business Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercializa...

ACOGF - Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing, the Company is...

ACOGF - Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) ...

ACOGF - Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of US$0.22 per unit. Each unit wil...

ACOGF - Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...

ACOGF - Expected US Company Earnings on Monday, November 27th, 2023

Nippon Paint Holdings Co. Ltd. (NPCPF) is expected to report for Q3 2023 SMC Corporation ADR (SMCAY) is expected to report for Q2 2024 Arcimoto Inc. (FUV) is expected to report for Q3 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-09-30 ...

ACOGF - Expected earnings - Alpha Cognition Inc

Alpha Cognition Inc (ACOGF) is expected to report for Q3 2023

ACOGF - Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering

Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a third closing pursuant to its previously announced private placement of units of the Company. Pursuant to the third closing, the Company is...

Previous 10 Next 10